NASDAQ:IFRX InflaRx Q4 2024 Earnings Report $1.72 +0.01 (+0.58%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$1.76 +0.04 (+2.44%) As of 10/2/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast InflaRx EPS ResultsActual EPS-$0.09Consensus EPS -$0.27Beat/MissBeat by +$0.18One Year Ago EPSN/AInflaRx Revenue ResultsActual RevenueN/AExpected Revenue$0.13 millionBeat/MissN/AYoY Revenue GrowthN/AInflaRx Announcement DetailsQuarterQ4 2024Date3/20/2025TimeBefore Market OpensConference Call DateThursday, March 20, 2025Conference Call Time9:30AM ETUpcoming EarningsInflaRx's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(20-F) InflaRx Earnings HeadlinesCritical Analysis: TScan Therapeutics (NASDAQ:TCRX) and InflaRx (NASDAQ:IFRX)October 3 at 2:15 AM | americanbankingnews.comInflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President and Global Head of Clinical DevelopmentOctober 2 at 12:58 AM | marketscreener.comMLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 3 at 1:00 AM | InvestorPlace (Ad)InflaRx N.V. Selected for Late-Breaking Kidney Week 2026 Poster on Izicopan Kidney Disease ModelsOctober 2 at 7:51 AM | quiverquant.comQInflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026October 2 at 7:30 AM | globenewswire.comInflaRx N.V.: InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical DevelopmentOctober 1 at 12:05 PM | finanznachrichten.deSee More InflaRx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like InflaRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InflaRx and other key companies, straight to your email. Email Address About InflaRxInflaRx (NASDAQ:IFRX) (NASDAQ: IFRX) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company’s research centers on the complement system, an important part of the immune response, with particular emphasis on blocking the activity of complement component C5a, which can contribute to excessive inflammation and tissue damage. InflaRx’s lead product candidate is vilobelimab, a monoclonal antibody designed to selectively inhibit C5a while preserving other aspects of the complement system. Vilobelimab received U.S. Food and Drug Administration emergency use authorization under the name Gohibic for certain critically ill adults hospitalized with COVID-19. The company has also evaluated vilobelimab in other serious inflammatory conditions, including hidradenitis suppurativa, ANCA-associated vasculitis and pyoderma gangrenosum. InflaRx was founded in 2007 and is headquartered in Jena, Germany, with operations serving the global biopharmaceutical market. The company continues to advance complement-targeted treatments through clinical development and research programs, including potential next-generation therapies intended to address inflammatory diseases with significant unmet medical needs. InflaRx is led by Chief Executive Officer and co-founder Niels Riedemann, M.D.View InflaRx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
